-
Je něco špatně v tomto záznamu ?
Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
B. Burkhardt, M. Taj, N. Garnier, V. Minard-Colin, V. Hazar, K. Mellgren, T. Osumi, A. Fedorova, N. Myakova, J. Verdu-Amoros, M. Andres, E. Kabickova, A. Attarbaschi, AKS. Chiang, E. Bubanska, S. Donska, LL. Hjalgrim, J. Wachowiak, A. Pieczonka,...
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
DKS 2014.11A/B, DKS 2016.24A/B
Deutsche Kinderkrebsstiftung
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
33923026
DOI
10.3390/cancers13092075
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.
2nd Department of Pediatrics Semmelweis University 1085 Budapest Hungary
Children's Cancer Centre National Centre for Child Health and Development Tokyo 104 0045 Japan
Department of Pediatric Hematology and Oncology Oslo University Hospital 0424 Oslo Norway
Department of Pediatric Hematology and Oncology University Hospital Valencia 46010 Valencia Spain
Department of Pediatric Oncology Royal Marsden Hospital Surrey SM2 5PT UK
Department of Pediatric Oncology University Children's Hospital Zurich 8032 Zürich Switzerland
Department of Pediatric Oncology University Hospital Le Fe 46026 Valencia Spain
Department of Pediatrics and Adolescent Medicine 2100 Copenhagen Denmark
Hannover Medical School Department of Pediatric Hematology and Oncology 30625 Hannover Germany
Hospices Civils de Lyon Institute of Pediatric Hematology and Oncology 69002 Lyon France
National Research Centre for Pediatric Hematology Oncology and Immunology 129090 Moscow Russia
Pediatric Hematology and Oncology University Medical Centre Hamburg Eppendorf 20246 Hamburg Germany
Princess Máxima Centre for Pediatric Oncology 3584 CS Utrecht The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21017892
- 003
- CZ-PrNML
- 005
- 20210729104051.0
- 007
- ta
- 008
- 210726s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers13092075 $2 doi
- 035 __
- $a (PubMed)33923026
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Burkhardt, Birgit $u Department of Pediatric Hematology, Oncology and BMT, University Hospital Muenster, 48149 Münster, Germany
- 245 10
- $a Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations / $c B. Burkhardt, M. Taj, N. Garnier, V. Minard-Colin, V. Hazar, K. Mellgren, T. Osumi, A. Fedorova, N. Myakova, J. Verdu-Amoros, M. Andres, E. Kabickova, A. Attarbaschi, AKS. Chiang, E. Bubanska, S. Donska, LL. Hjalgrim, J. Wachowiak, A. Pieczonka, A. Uyttebroeck, J. Lazic, J. Loeffen, J. Buechner, F. Niggli, M. Csoka, G. Krivan, J. Palma, GAA. Burke, A. Beishuizen, K. Koeppen, S. Mueller, H. Herbrueggen, W. Woessmann, M. Zimmermann, A. Balduzzi, M. Pillon
- 520 9_
- $a Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Taj, Mary $u Department of Pediatric Oncology, Royal Marsden Hospital, Surrey SM2 5PT, UK
- 700 1_
- $a Garnier, Nathalie $u Hospices Civils de Lyon, Institute of Pediatric Hematology and Oncology, 69002 Lyon, France
- 700 1_
- $a Minard-Colin, Veronique $u Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France
- 700 1_
- $a Hazar, Volkan $u Memorial Healthcare Group Private Antalya Yildiz Hospital, Pediatric Oncology Unit, Antalya 07070, Turkey
- 700 1_
- $a Mellgren, Karin $u Department of Pediatric Oncology and Hematology, Sahlgrenska University Hospital, The Queen Silvia Children's Hospital, 41685 Gothenburg, Sweden
- 700 1_
- $a Osumi, Tomoo $u Children's Cancer Centre, National Centre for Child Health and Development, Tokyo 104-0045, Japan
- 700 1_
- $a Fedorova, Alina $u Belarusian Research Centre for Pediatric Oncology, Hematology and Immunology, Research Department, 223053 Minsk, Belarus
- 700 1_
- $a Myakova, Natalia $u National Research Centre for Pediatric Hematology, Oncology and Immunology, 129090 Moscow, Russia
- 700 1_
- $a Verdu-Amoros, Jaime $u Department of Pediatric Hematology and Oncology, University Hospital Valencia, 46010 Valencia, Spain
- 700 1_
- $a Andres, Mara $u Department of Pediatric Oncology, University Hospital Le Fe, 46026 Valencia, Spain
- 700 1_
- $a Kabickova, Edita $u Department of Pediatric Hematology and Oncology, Charles University & University Hospital Motol, 150 06 Prague, Czech Republic
- 700 1_
- $a Attarbaschi, Andishe $u St. Anna Children's Hospital, Department of Paediatric Haematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria
- 700 1_
- $a Chiang, Alan Kwok Shing $u Department of Pediatrics & Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
- 700 1_
- $a Bubanska, Eva $u Clinic of Pediatric Oncology and Hematology, Slovak Health University and Children's Faculty Hospital, 97409 Banská Bystrica, Slovakia
- 700 1_
- $a Donska, Svetlana $u Centre of Pediatric OncoHematology and BMT, National Ukrainian Children's Hospital Ochmatdyt, 04070 Kiev, Ukraine
- 700 1_
- $a Hjalgrim, Lisa Lyngsie $u Department of Pediatrics and Adolescent Medicine, 2100 Copenhagen, Denmark
- 700 1_
- $a Wachowiak, Jacek $u Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, 60572 Poznan, Poland
- 700 1_
- $a Pieczonka, Anna $u Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, 60572 Poznan, Poland
- 700 1_
- $a Uyttebroeck, Anne $u Department of Pediatric Hematology and Oncology, University Hospital Leuven, KU Leuven, 3000 Leuven, Belgium
- 700 1_
- $a Lazic, Jelena $u Department for Hematology and Oncology, University Children's Hospital, School of Medicine, University of Belgrade, 11000 Belgrade, Serbia
- 700 1_
- $a Loeffen, Jan $u Princess Máxima Centre for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a Buechner, Jochen $u Department of Pediatric Hematology and Oncology, Oslo University Hospital, 0424 Oslo, Norway
- 700 1_
- $a Niggli, Felix $u Department of Pediatric Oncology, University Children's Hospital Zurich, 8032 Zürich, Switzerland
- 700 1_
- $a Csoka, Monika $u 2nd Department of Pediatrics, Semmelweis University, 1085 Budapest, Hungary
- 700 1_
- $a Krivan, Gergely $u Central Hospital of Southern Pest-National Institute of Hematology and Infectious Diseases, Department for Pediatric Hematology and Hemopoietic Stem Cell Transplantation, 1097 Budapest, Hungary
- 700 1_
- $a Palma, Julia $u Faculty of Medicine, Hospital Luis Calvo Mackenna, Department of Pediatrics-Bone Marrow Transplantation Unit, University of Chile, Santiago 8820808, Chile
- 700 1_
- $a Burke, G A Amos $u Department of Pediatric Haematology and Oncology and Palliative Care, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
- 700 1_
- $a Beishuizen, Auke $u Princess Máxima Centre for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a Koeppen, Kristin $u Department of Pediatric Hematology, Oncology and BMT, University Hospital Muenster, 48149 Münster, Germany
- 700 1_
- $a Mueller, Stephanie $u Department of Pediatric Hematology, Oncology and BMT, University Hospital Muenster, 48149 Münster, Germany
- 700 1_
- $a Herbrueggen, Heidi $u Department of Pediatric Hematology, Oncology and BMT, University Hospital Muenster, 48149 Münster, Germany
- 700 1_
- $a Woessmann, Wilhelm $u Pediatric Hematology and Oncology, University Medical Centre Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany
- 700 1_
- $a Zimmermann, Martin $u Hannover Medical School, Department of Pediatric Hematology and Oncology, 30625 Hannover, Germany
- 700 1_
- $a Balduzzi, Adriana $u Pediatric Hematology and Oncology, Clinica Pediatrica Università degli Studi di Milano Bicocca, Fondazione MBBM, Ospedale San Gerardo, 20126 Monza, Italy
- 700 1_
- $a Pillon, Marta $u Department of Child and Woman Health, Oncology Hematology Division, University-Hospital of Padua, 35125 Padua, Italy
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 9 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33923026 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210726 $b ABA008
- 991 __
- $a 20210729104050 $b ABA008
- 999 __
- $a ind $b bmc $g 1676458 $s 1138334
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 9 $e 20210425 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a DKS 2014.11A/B, DKS 2016.24A/B $p Deutsche Kinderkrebsstiftung
- LZP __
- $a Pubmed-20210726
